news & Updates
CARTA Trials
Offered as of: June 7, 2023
Cachexia Study
A new trial looking for patients with advanced cancer, who have developed Cachexia. As cancer progresses patients frequently develop cachexia, a loss of weight due to catabolism of muscle and fat tissue. The progressive worsening of cachexia impacts a cancer patient’s quality of life and contributes to poor survival. Cachexia patients may be eligible to receive a study medication looking to help these patients gain weight and may lead to improvement in serious aspects of cachexia, such as anorexia leading to unintended weight loss, fatigue, and impaired mobility.
The medication being studied is called Ponsegromab. Patients will participate in the initial 12 week study and if they decide they will enter an open label phase for an additional year.
For patients to be eligible, they must be over the age of 18, have had a diagnosis of pulmonary cancer, pancreatic cancer or colorectal cancer. They must have demonstrated weight loss of 5% of their body weight in the last six months.
All study related procedures, as well as the study medication is at no cost to the patient.
Crohns & Ulcerative Colitis Trial
CARTA is conducting a Phase 3 clinical study in Crohn's & Ulcerative Colitis disease patients. Patients who are currently suffering from moderate to severe symptoms and are considered to be in "flare" will be eligible to participate in this clinical study. A new treatment being studied for Crohn's and UC may significantly reduce these symptoms and provide a better quality of life.
